3SBio gains Verseau's macrophage checkpoint modulators for cancer

With a deal to license macrophage checkpoint modulators, 3SBio Inc. (HKSE:1530) is bypassing the standard roster of T cell targets and jumping to the next wave of immuno-oncology targets. The company is gaining exclusive access to mAb inhibitors against macrophage checkpoints from Verseau Therapeutics Inc. (Boston, Mass.).